• Clinical Insights: February 5, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval FirvanqTM (vancomycin hydrochloride) – January 29, 2018 – CutisPharma announced that the U.S. Food and Drug Administration (FDA) has approved Firvanq™ (vancomycin hydrochloride) for oral solution, for the… Read more »

  • Clinical Insights: January 15, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Formulation Approval No new updates.   New Indication Approval Lynparza® (olaparib) – January 12, 2018 – The Food and Drug Administration… Read more »

  • Join Us at the 340B Coalition Winter Conference!

    Join the RxStrategies team at the 340B Coalition Winter Conference in San Diego, California February 21-23. Here, your team can stay up to date on the latest news, trends and regulations in the 340B program to best maintain compliance. We look forward to connecting with industry leaders while gaining insight on 340B happenings and issues… Read more »

  • Clinical Insights: January 2, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lumify™ (brimonidine tartrate) – New OTC Drug Approval – December 22, 2017 – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary… Read more »

  • Clinical Insights: December 12, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lonhala™ Magnair™ (glycopyrrolate) – December 5, 2017 – Sunovion Pharmaceuticals Inc. (Sunovion) announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application… Read more »

  • Ensure and Maximize 340B Program Compliance

    We assist retail and specialty pharmacies in ensuring 340B program security, efficiency and safety. With this solution, you will be able to maximize compliance, visibility, capture rate, inventory reconciliation and more.   Key Elements of Our Enterprise Backbone for Retail and Specialty Pharmacies • Serves as data clearinghouse for all your contracted TPAs (Third Party… Read more »

  • Clinical Insights: November 13, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Heplisav-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] – New Vaccine Approval – November 9, 2017 – Dynavax Technologies Corporation announced that the U.S. Food and Drug Administration… Read more »

  • Clinical Insights: October 24, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Shingrix (Zoster Vaccine Recombinant, Adjuvanted) – New Vaccine Approval – October 20, 2017 – GlaxoSmithKline plc announced that the U.S. Food and Drug Administration (FDA) has… Read more »